By deciphering the multifaceted dynamics of MYC and RAS cooperation, this review seeks to provide insights into potential therapeutic vulnerabilities and opportunities for developing novel precision medicine approaches to combat malignancies driven by MYC and KRAS dysregulation, able to improve treatment outcomes and address the challenge of therapy resistance in cancer. This evidence concerns the gene MYC and cancer.